Editas Medicine Stock Probability of Future Stock Price Finishing Over 15.84
| EDIT Stock | USD 1.99 0.11 5.24% |
Closest to current price Editas long CALL Option Payoff at Expiration
Editas |
Editas Medicine Target Price Odds to finish over 15.84
The tendency of Editas Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 15.84 or more in 90 days |
| 1.99 | 90 days | 15.84 | close to zero percent |
Based on a normal probability distribution, the odds of Editas Medicine to move over $ 15.84 or more in 90 days from now is close to zero percent (This Editas Medicine probability density function shows the probability of Editas Stock to fall within a particular range of prices over 90 days) . Probability of Editas Medicine price to stay between its current price of $ 1.99 and $ 15.84 at the end of the 90-day period is about 98.0 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.99 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Editas Medicine will likely underperform. Additionally Editas Medicine has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Editas Medicine Price Density |
| Price |
Predictive Modules for Editas Medicine
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Editas Medicine. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Editas Medicine Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Editas Medicine is not an exception. The market had few large corrections towards the Editas Medicine's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Editas Medicine, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Editas Medicine within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.91 | |
β | Beta against Dow Jones | 1.99 | |
σ | Overall volatility | 0.55 | |
Ir | Information ratio | -0.17 |
Editas Medicine Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Editas Medicine for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Editas Medicine can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Editas Medicine generated a negative expected return over the last 90 days | |
| Editas Medicine may become a speculative penny stock | |
| Editas Medicine has high historical volatility and very poor performance | |
| Editas Medicine has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 78.12 M. Net Loss for the year was (153.22 M) with loss before overhead, payroll, taxes, and interest of (155.25 M). | |
| Editas Medicine currently holds about 452.56 M in cash with (132.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.59, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 71.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Editas Stock Rises on Updated Data From SCD Study of Reni-Cel |
Editas Medicine Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Editas Stock often depends not only on the future outlook of the current and potential Editas Medicine's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Editas Medicine's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 76 M | |
| Cash And Short Term Investments | 323.1 M |
Editas Medicine Technical Analysis
Editas Medicine's future price can be derived by breaking down and analyzing its technical indicators over time. Editas Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Editas Medicine. In general, you should focus on analyzing Editas Stock price patterns and their correlations with different microeconomic environments and drivers.
Editas Medicine Predictive Forecast Models
Editas Medicine's time-series forecasting models is one of many Editas Medicine's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Editas Medicine's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Editas Medicine
Checking the ongoing alerts about Editas Medicine for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Editas Medicine help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Editas Medicine generated a negative expected return over the last 90 days | |
| Editas Medicine may become a speculative penny stock | |
| Editas Medicine has high historical volatility and very poor performance | |
| Editas Medicine has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 78.12 M. Net Loss for the year was (153.22 M) with loss before overhead, payroll, taxes, and interest of (155.25 M). | |
| Editas Medicine currently holds about 452.56 M in cash with (132.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.59, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 71.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Editas Stock Rises on Updated Data From SCD Study of Reni-Cel |
Additional Tools for Editas Stock Analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.